About multiple sclerosis, natalizumab, and CD34+ hematopoietic progenitors.
Carine
C
Vuaillat
Géraldine
G
Androdias
Nathalie
N
Davoust
Serge
S
Nataf
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D018952:Antigens, CD34 / Q000097:blood*; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000097:blood / Q000188:drug therapy; D019650:Hematopoietic Stem Cell Mobilization; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells / Q000187:drug effects* / Q000276:immunology; D006801:Humans; D051379:Mice; D009103:Multiple Sclerosis / Q000097:blood* / Q000188:drug therapy*; D000069442:Natalizumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018952:Antigens, CD34; D000069442:Natalizumab